Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03257358 · ClinicalTrials.gov registry record · Phase 4
A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 382
- Enrollment target
NCT03257358 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 382 participants.
The verdict
NCT03257358, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 382 participants
- Enrollment target
Study Summary
A study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod
Interventions
- DRUG Fingolimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 382 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2019-06-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03257358
The ClinicalTrials.gov registry entry for NCT03257358 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 382 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fingolimod is the first listed.
NCT03257358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03257358 about?
NCT03257358 is a clinical study titled "A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod". A study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod
What is the current status of trial NCT03257358?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 382 participants. The study started on 2017-09-19. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT03257358?
The interventions under investigation include: Fingolimod (DRUG).
Who is sponsoring clinical trial NCT03257358?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.